ZTS
Zoetis
October 15, 2026 · market open
- Rarity
- 1.29
- Peak move
- +4.90%
- Float cap
- $31.8B
Zoetis is a global animal health company that discovers, develops and manufactures medicines, vaccines, diagnostics and genetic tests. It sells to veterinarians, pet owners and livestock producers across eight core species: dogs, cats and horses on the companion-animal side, and cattle, swine, poultry, fish and sheep on the livestock side. Products reach more than 100 countries, with major brands including Apoquel, Simparica and Cytopoint.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 0 timed with the moveregulatory_approvalThe FDA issued an Emergency Use Authorization to Zoetis for Simparica TRIO (sarolaner, moxidectin, pyrantel chewable tablets) to treat New World screwworm (myiasis) infestations in dogs and puppies, authorized August 13, 2026.
peer_disclosureThe FDA issued an Emergency Use Authorization to Elanco US Inc. for CLiK Extra (dicyclanil topical suspension) wound spray to prevent New World screwworm myiasis in sheep, cattle, goats, swine, camelids and certain wildlife.
regulatory_approvalZoetis received expanded label approval from the USDA Center for Veterinary Biologics for Poulvac Bron GA08, allowing use in healthy chickens 1 day and older against infectious bronchitis Georgia 2008 type via coarse spray and DMV/1639 type via oral droplet.
board_changeZoetis appointed Iris Knobloch, president of the Festival de Cannes and a director at Deezer, Lazard and Vail Resorts, to its Board of Directors effective December 1, 2026, expanding the board from 12 to 13 members; she will serve on the Corporate Governance Committee.
dividend_changeZoetis' Board of Directors declared a fourth quarter 2026 dividend of $0.53 per share, payable December 1, 2026 to shareholders of record at the close of business on October 30, 2026.
clinical_readoutZoetis reported new peer-reviewed data finding Simparica Trio provided stronger protection against a resistant heartworm strain than competitor NexGard Plus.